Exact Sciences' New Blood Test Can Detect Cancers Earlier

Fifty cancer types in one liquid biopsy test: Exact Sciences enters early-detection market

Liquid biopsy test Cancerguard can scan for 50 cancers in one blood sample. The company says it marks a new era in early detection, but there are caveats.

Exact Sciences' new blood test can detect cancers earlier

Cancerguard is a blood test designed for the early detection of cancers like pancreatic, ovarian, liver, stomach and esophageal.

Exact Sciences launches Cancerguard blood test

Cancerguard is the first commercially available multi-cancer early detection blood test that analyzes multiple biomarker classes to help detect a wide range of cancers.

In Business: Exact Sciences launches Cancerguard blood test - Wisconsin Technology Council

Exact Sciences Corp. on Wednesday announced the launch of the Cancerguard test, a new multi-cancer early detection blood test that is now available as a laboratory-developed test in the United States. Cancerguard is the first MCED test commercially available that analyzes multiple biomarker classes to help detect a wide range of cancers, including those that often

Exact Sciences Unveils Cancerguard A Game-Changer in Multi-Cancer Detection During Significant Revenue Surge,

Exact Sciences Launches Groundbreaking Cancerguard Test: Pioneering Multi-Cancer Early Detection Amidst Revenue Growth In a significant advancement within the cancer diagnostics landscape, Exact Sciences Corp. (Nasdaq: EXAS), headquartered in Madison, Wisconsin, has officially launched Cancerguard, a cutting-edge multi-cancer early detection (MCED) blood test. This test is now available as a laboratory-developed test (LDT) in the United States, …

Detect 50+ Cancer Types From a Single Blood Draw: Exact Sciences' New Test Shows 97.4% Accuracy

Revolutionary Cancerguard blood test detects 50+ cancer types with 97.4% specificity. Priced at $689, available at 7,000 Quest locations. Shows 68% sensitivity for deadliest cancers, could reduce Stage IV diagnoses by 42%.